Celator Pharmaceuticals, Inc.  


Company Name:
Celator Pharmaceuticals, Inc.   
Sector:
Healthcare 
Transaction Type:
Follow-on Offering 
Ticker Symbol:
CPXX 
Deal Amount:
$43.7M
Transaction Date:
3/23/2016 
Transaction Summary:
Celator Pharmaceuticals, Inc. raised $43.7 million in its follow-on offering at $9.50 per share. Needham acted as lead manager on the transaction. The Company’s underwriters fully exercised their option to purchase an additional 600,000 shares of common stock at the follow-on offering price to cover over-allotments. The net proceeds from the sale of the shares from the offering will be used by Celator Pharmaceuticals, Inc. to fund initial launch activities, commercialization of VYXEOS, advance the pipeline of clinical stage assets and for general corporate purposes. 
Company Description:
Celator Pharmaceuticals, Inc. (NASDAQ: CPXX), with locations in Ewing, N.J., and Vancouver, B.C., is an oncology-focused biopharmaceutical company that is transforming the science of combination therapy, and developing products to improve patient outcomes in cancer. Celator's proprietary technology platform, CombiPlex®, enables the rational design and rapid evaluation of optimized combinations of anti-cancer drugs, incorporating traditional chemotherapies as well as molecularly targeted agents to deliver enhanced anti-cancer activity. CombiPlex addresses several fundamental shortcomings of conventional combination regimens, as well as the challenges inherent in combination drug development, by identifying the most effective synergistic molar ratio of the drugs being combined in vitro, and fixing this ratio in a nano-scale drug delivery complex to maintain the optimized combination after administration and ensuring exposure of this ratio to the tumor. Celator's lead product is VYXEOS™ (also known as CPX-351), a nano-scale liposomal formulation of cytarabine:daunorubicin in Phase 3 clinical testing for the treatment of acute myeloid leukemia. We have also conducted clinical development on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine studied in colorectal cancer; and have a preclinical stage product candidate, CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. More recently, the Company has advanced its CombiPlex platform and broadened its application to include molecularly targeted therapies. 
Investment Banking